AB | BC | MB | NB | NL | NS | NT | ON | PE | QC | SK | YT

News & Announcements

2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008


Information Update
January 19, 2017

Health Canada advises that the drug hCG is not authorized or proven effective for weight loss

At this time of year, when some are considering weight loss options, Health Canada wishes to advise Canadians that hCG (human chorionic gonadotropin) is not authorized or proven as a weight loss aid, and could pose serious health risks.

hCG is a prescription drug authorized in Canada as an injectable for the treatment of hormone-related conditions such as infertility. It should be used only under the supervision of a healthcare professional.

Health Canada Information Update

January 17, 2017

Unauthorized health product "Blow" may pose serious health risks

Health Canada is advising Canadians that it has seized the unauthorized health product “Blow”, by Limitless Pharma, from Atomik Nutrition at 450 Boulevard de Mortagne, Boucherville, QC. “Blow” is promoted as a pre-workout supplement and is labelled to contain the unauthorized drug 1,3 Dimethylamylamine (DMAA), which may pose serious health risks such as high blood pressure and stroke.

Health Canada Advisory

Foreign Product Alert
January 13, 2017

Health Canada is advising Canadians not to use these foreign health products as they may pose a health risk. These products have been found by regulators in other countries to contain undeclared drug ingredients or heavy metals. Prescription drugs should only be taken under the supervision of a health care practitioner.

These products are not authorized for sale in Canada and have not been found on the Canadian market, but they may have been brought into the country by travellers or purchased over the Internet.

Health Canada Foreign Product Alert

Health Product Risk Communication
January 10, 2017

Erwinase for Injection - Shortage and Special Handling Instructions- Jazz Pharmaceuticals

To avoid potential product shortage of ERWINASE,  Health Canada has facilitated the temporary importation of UK-labelled product from Batch CAMR-179G for use with a 5-micron filter. Small amounts of particulate matter have been observed bound to the stopper and/or present on the lyophilized cake of some vials of ERWINASE from BATCH 179G.

Health Canada Health Product Risk Communication

Information Update
January 06, 2017

New safety information on injectable gadolinium-based contrast agents used in MRI scans

Health Canada has conducted a safety review of gadolinium-based contrast agents (GBCAs) due to growing scientific evidence that gadolinium may accumulate in the brain following multiple magnetic resonance imaging (MRI) scans. Although no health consequences have been identified with gadolinium accumulation in the brain, Health Canada will be working with Canadian manufacturers to update the labelling of GBCAs to include this new information.

Health Canada Information Update